These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 11083773)

  • 21. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission.
    Blagborough AM; Yoshida S; Sattabongkot J; Tsuboi T; Sinden RE
    Vaccine; 2010 Aug; 28(37):6014-20. PubMed ID: 20637303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization.
    Miyata T; Harakuni T; Tsuboi T; Sattabongkot J; Kohama H; Tachibana M; Matsuzaki G; Torii M; Arakawa T
    Infect Immun; 2010 Sep; 78(9):3773-82. PubMed ID: 20584978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A rapid genotyping method for the vivax malaria transmission-blocking vaccine candidates, Pvs25 and Pvs28.
    Tsuboi T; Kaneko O; Cao YM; Tachibana M; Yoshihiro Y; Nagao T; Kanbara H; Torii M
    Parasitol Int; 2004 Sep; 53(3):211-6. PubMed ID: 15468527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.
    Mizutani M; Iyori M; Blagborough AM; Fukumoto S; Funatsu T; Sinden RE; Yoshida S
    Infect Immun; 2014 Oct; 82(10):4348-57. PubMed ID: 25092912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequence polymorphisms of Plasmodium vivax ookinete surface proteins (Pvs25 and Pvs28) from clinical isolates in Korea.
    Han ET; Lee WJ; Sattabongkot J; Jang JW; Nam MH; An SS; Suh I; Lim CS
    Trop Med Int Health; 2010 Sep; 15(9):1072-6. PubMed ID: 20545923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T; Harakuni T; Sugawa H; Sattabongkot J; Kato A; Tachibana M; Torii M; Tsuboi T; Arakawa T
    Vaccine; 2011 Mar; 29(15):2720-6. PubMed ID: 21315699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms of Plasmodium vivax ookinete (sexual stage) surface proteins (Pvs25 and Pvs28) from Thailand.
    Kuesap J; Suphakhonchuwong N; Rungsihirunrat K
    Infect Genet Evol; 2024 Mar; 118():105558. PubMed ID: 38244749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites.
    Bauza K; Malinauskas T; Pfander C; Anar B; Jones EY; Billker O; Hill AV; Reyes-Sandoval A
    Infect Immun; 2014 Mar; 82(3):1277-86. PubMed ID: 24379295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
    Wu Y; Ellis RD; Shaffer D; Fontes E; Malkin EM; Mahanty S; Fay MP; Narum D; Rausch K; Miles AP; Aebig J; Orcutt A; Muratova O; Song G; Lambert L; Zhu D; Miura K; Long C; Saul A; Miller LH; Durbin AP
    PLoS One; 2008 Jul; 3(7):e2636. PubMed ID: 18612426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of two Plasmodium vivax sexual stage antigens as transmission-blocking vaccine candidates.
    Zhang Y; Liu F; Zhao Y; Yang F; Bai J; Jia X; Roobsoong W; Sattabongkot J; Cui L; Cao Y; Luo E; Wang M
    Parasit Vectors; 2021 Aug; 14(1):407. PubMed ID: 34399829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of the Transmission-Blocking Vaccine Candidates Pvs28 and Pvs25 in Plasmodium vivax: Geographic Differentiation and Evidence of Positive Selection.
    Chaurio RA; Pacheco MA; Cornejo OE; Durrego E; Stanley CE; Castillo AI; Herrera S; Escalante AA
    PLoS Negl Trop Dis; 2016 Jun; 10(6):e0004786. PubMed ID: 27347876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit.
    Valderrama-Aguirre A; Quintero G; Gómez A; Castellanos A; Pérez Y; Méndez F; Arévalo-Herrera M; Herrera S
    Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):16-24. PubMed ID: 16291762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720.
    Saul A; Hensmann M; Sattabongkot J; Collins WE; Barnwell JW; Langermans JA; Wu Y; Long CA; Dubovsky F; Thomas AW
    Parasite Immunol; 2007 Oct; 29(10):525-33. PubMed ID: 17883455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development.
    Miyata T; Harakuni T; Tsuboi T; Sattabongkot J; Ikehara A; Tachibana M; Torii M; Matsuzaki G; Arakawa T
    Infect Immun; 2011 Oct; 79(10):4260-75. PubMed ID: 21807905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy model for mosquito stage transmission blocking vaccines for malaria.
    Saul A
    Parasitology; 2008 Nov; 135(13):1497-506. PubMed ID: 18257944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.
    Blagborough AM; Musiychuk K; Bi H; Jones RM; Chichester JA; Streatfield S; Sala KA; Zakutansky SE; Upton LM; Sinden RE; Brian I; Biswas S; Sattabonkot J; Yusibov V
    Vaccine; 2016 Jun; 34(28):3252-9. PubMed ID: 27177945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blocking effect of a monoclonal antibody against recombinant Pvs25 on sporozoite development in Anopheles sinensis.
    Moon SU; Kim HH; Kim TS; Choi KM; Oh CM; Ahn YJ; Hwang SK; Sohn Y; Shin EH; Kim H; Lee HW
    Clin Vaccine Immunol; 2010 Aug; 17(8):1183-7. PubMed ID: 20554802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant Pvs48/45 antigen expressed in E. coli generates antibodies that block malaria transmission in Anopheles albimanus mosquitoes.
    Arévalo-Herrera M; Vallejo AF; Rubiano K; Solarte Y; Marin C; Castellanos A; Céspedes N; Herrera S
    PLoS One; 2015; 10(3):e0119335. PubMed ID: 25775466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei.
    Cao Y; Hayashi CTH; Kumar N
    J Infect Dis; 2024 Jun; 229(6):1894-1903. PubMed ID: 38408353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the antibody responses to Plasmodium vivax and Plasmodium falciparum antigens in residents of Mandalay, Myanmar.
    Kim TS; Kim HH; Kim JY; Kong Y; Na BK; Lin K; Moon SU; Kim YJ; Kwon MH; Sohn Y; Kim H; Lee HW
    Malar J; 2011 Aug; 10():228. PubMed ID: 21819610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.